Poland· PL-100455264
Evkeeza
A evinacumab product containing evinacumabum, registered in Poland by Ultragenyx Germany GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Evinacumab is registered in 12 of 19 countries.
Countries holding a registration under ATC C10AX17 (evinacumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Evinacumab · ATC C10AX17
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Evinacumabum
- Manufacturer
- Ultragenyx Germany GmbH
- Country
- Poland (PL)
- ATC code
- C10AX17
- ATC class
- Evinacumab
- Defined daily dose
- 37.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin04062343002024
- gtin04062343002086
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Evinacumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEvkeeza 150 mg/mlUltragenyx Germany
- CzechiaEVKEEZAUltragenyx Germany GmbH, Berlín
- United StatesEvkeezaRegeneron Pharmaceuticals, Inc.
- IrelandEvkeeza 150 mg/ml concentrate for solution for infusionUltragenyx Germany GmbH
- IcelandEvkeezaUltragenyx Germany GmbH
- NorwayEvkeezaUltragenyx Germany GmbH
- SwedenEvkeeza 150 mg/ml Koncentrat till infusionsvätska, lösningUltragenyx Germany GmbH
- FinlandEvkeezaUltragenyx Germany GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Evkeeza
- Liechtenstein · Evkeeza
- Norway · Evkeeza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c69d6524-80f9-42f3-a3df-37a704ffd81a GET /v1/drugs/c69d6524-80f9-42f3-a3df-37a704ffd81a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "150 mg/ml",
"packaging": "Rpz ¦ EU/1/21/1551/002 ¦ 141064\n1 fiol. 8 ml\nRpz ¦ EU/1/21/1551/001 ¦ 141065\n1 fiol. 2,3 ml\n¦ UR/Z/4c/192/24 - 04062343002024 ¦ UR/Z/4c/133/25 - 04062343002024 ¦ UR/Z/4c/217/25 - 04062343002086 ¦ UR/Z/4c/053/26 - 04062343002086 ¦ UR/Z/4c/153/26 - 04062343002086 ¦ UR/Z/4c/196/26 - 04062343002086",
"substance": "Evinacumabum 150 mg/ml",
"common_name": "Evinacumabum",
"pl_product_id": "100455264",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about evinacumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.